LG CNS launches AI drug discovery platform for Korea's Dong-A Socio Group

LG CNS has developed an AI-driven drug discovery platform for South Korea's Dong-A Socio Group that integrates drug research data and uses AI to accelerate and improve the accuracy of candidate substance identification, validation, and efficacy prediction, reducing time and costs in new drug development.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.